☆ 4.4 Article

Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells

CLINICAL LUNG CANCER (2021)

Get Full Text
Add to Collection

Journal

CLINICAL LUNG CANCER
Volume 22, Issue 4, Pages E487-E497

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2020.10.018

Keywords

Biomarker; Chemotherapy; Immunomodulation; Immunotherapy; Immune checkpoint inhibitor

Categories

Oncology

Funding

  1. BMS-OSU collaborative research grant
  2. RW's internal OSU-CCC award
  3. BMS
  4. OSU K12 Training Grant [K12 CA133250]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.